14 articles with Yuhan Corporation
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation
Boehringer Ingelheim focuses on the development of next generation NASH treatments that target all three key drivers of the disease - steatosis, inflammation and fibrosis
Biotech and pharma companies came roaring out of the gate on the first day of the annual J.P. Morgan Healthcare Conference with big deals, expansions and promises of growth and pipeline sustainability.
Gilead Sciences is acquiring the global rights to develop and commercialize novel small molecules against two targets from Yuhan Corporation, based in South Korea. They drugs will be developed to treat advanced fibrosis related to nonalcoholic steatohepatitis (NASH).
Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
Gilead Sciences, Inc. and Yuhan Corporation today announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH).
Janssen agreed to pay Yuhan $50 million in upfront money. Yuhan said that Janssen will be responsible for the development of lazertinib. Janssen will also be responsible for manufacturing and commercialization of the drug.
YUHAN ANNOUNCES LICENSE AND COLLABORATION AGREEMENT WITH JANSSEN FOR A NOVEL, INVESTIGATIONAL LUNG CANCER THERAPY
Yuhan will receive an upfront payment of $50 million and is eligible to receive up to $1,205 million in potential development and commercial milestone payments, along with tiered double-digit royalties on future net sales.
Seoul Viosys Applies UV LED Technology 'Violeds' to Mosquito Trap Not Containing Chemical Components
Seoul Viosys announced that it has applied its advanced UV LED technology “Violeds” to mosquito trap of Yuhan Corporation, a pharmaceutical company in Korea.
Yuhan And Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. Enter Into Exclusive License And Co-Development Agreement For 3rd -Generation EGFR-Targeted Therapy In China
Han All Pharmaceutical Co., Ltd. And Yuhan Corporation Complete License Agreement For A Unique Cardiovascular Combination Product For The Korean Market